Dme Capital Management, LP Gain Therapeutics, Inc. Transaction History
Dme Capital Management, LP
- $2.4 Trillion
- Q3 2024
A detailed history of Dme Capital Management, LP transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Dme Capital Management, LP holds 566,130 shares of GANX stock, worth $900,146. This represents 0.04% of its overall portfolio holdings.
Number of Shares
566,130
Previous 566,130
-0.0%
Holding current value
$900,146
Previous $725 Million
39.06%
% of portfolio
0.04%
Previous 0.04%
Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
23Shares Held
2.39MCall Options Held
10KPut Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$935,5710.1% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$532,0010.01% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$432,4350.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA145KShares$230,8950.0% of portfolio
-
Telemetry Investments, L.L.C. New York, NY123KShares$195,5700.61% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $18.9M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...